Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Risankizumab · Skyrizi, ABBV-066

Monoclonal antibody · Antagonist of IL-23 p19 subunit · developed by Abbvie

Approved FDA, Apr 2019

ABBV Developer

1 Registered trials

What is Risankizumab?

Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that binds the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor, blocking IL-23-mediated signaling and pro-inflammatory cytokine release.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Skyrizi, ABBV-066, SKYRIZI
Drug type: Monoclonal antibody
Targets: IL-23 p19 subunit
Mechanism: Antagonist of IL-23 p19 subunit
Pathways: IL-23/IL-23 receptor signaling, Th17 cell development and activation, pro-inflammatory cytokine release
Therapy area: Gastroenterology
Developer: Abbvie Inc (ABBV)
FDA status: Approved as Skyrizi (April 23, 2019), BLA761105 · FDA label
UNII: 90ZX3Q3FR7

✅ FDA-approved uses

Moderate-to-severe plaque psoriasis
Active psoriatic arthritis
Moderately to severely active Crohn's disease
Moderately to severely active ulcerative colitis

From the indications section of the FDA label (version of Jun 15, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05995353	Phase 3	Crohn's Disease	Recruiting	ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Crohn's Disease

More from Abbvie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1 ABBV-438 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Risankizumab

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z